Trend of new antipsychotics in development for schizophrenia

International Medical Journal

Volumn 12, Issue 3, 2005, Pages 175-180

  Singh, Amarendra N ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Antipsychotics in development; Dopamine; Efficacy; Schizophrenia; Serotonin

Indexed keywords

2 PHENYL 4 [4 (2 PYRIMIDINYL) 1 PIPERAZINYLMETHYL]IMIDAZOLE; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA [1 [2 (1,4 BENZODIOXAN 5 YLOXY)ETHYL] 3 PYRROLIDINYL] 4 FLUOROACETOPHENONE; ASENAPINE; BIFEPRUNOX; BLONANSERIN; C 11007; CEP 1538; CLOZAPINE; CLOZAPREXIN; CYCLOSERINE; DAB 452; DOPAMINE RECEPTOR STIMULATING AGENT; ECOPIPAM; HALOPERIDOL; ILOPERIDONE; MAZAPERTINE; MODAFINIL; NEUROLEPTIC AGENT; OSANETANT; PALIPERIDONE; PANCREAS HORMONE; PARTIAL AGONIST; RG 1068; RIMONABANT; RISPERIDONE; SONEPIPRAZOLE; UNCLASSIFIED DRUG; Y 931;

AGITATION; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONFUSION; CONSCIOUSNESS DISORDER; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RESEARCH; FATIGUE; FEVER; HEADACHE; HEART VENTRICLE TACHYCARDIA; HUMAN; INDIGESTION; INSOMNIA; MUSCLE STIFFNESS; NAUSEA; PARESTHESIA; QUALITY OF LIFE; RELAPSE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SYNCOPE; WEIGHT GAIN;

EID: 26844457552     PISSN: 13412051     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Nicholson D. Asenapine: new hope for prescribers, families and patients with schizophrenia and bipolar disorder. Presentation by Senior VP Research. Organon, 2003.
2. Potkin SG, Alva G, Panagides J, Carreon DT, Langstrom B, Mukherjee J, de Greef R. Predicting clinical antipsychotic doses from preclinical and PET studies: a case study with asenapine. Poster presentation. 2003.
3. st Annual Meeting of the American College of Neuropsychopharmacology, Puerto Rico, December 8-12, 2002.
4. Andrew JS, Shahid M, Connick JH. Pharmacological profile of Org 5222, a novel atypical antipsychotic. Biological Psychiatry (Apr 15, 1999) 45(8S): 132(Suppl S). (abstract)
5. Andrew JS, Shahid M, Connick JH. Pharmacological profile of Org 5222, a novel atypical antipsychotic. Schizophrenia Research (Apr 1999) 36(1-3): 111-111 Sp. Iss. SI. (abstract)
6. Andree B, Halldin, C, Vrijmoedde Vries M, Farde L. Central 5-HT2A and D-2 dopamine receptor occupancy, after sublingual administration of ORG 5222 in healthy men. Psychopharmcology (Jun 1997) 131(4): 339-345.
7. Collie IT, Holt JD, Stam N, Roesink C, Hill DR, Shahid M. Binding profile of Org-5222 at cloned human dopamine D-2, D-3 and D-4 receptors. British Journal of Pharmacology (Dec 1995) 116: P380-P380 (Suppl S). (abstract)
8. Broekkamp CLE, Degraaf JS, Vandelft AML. Characterization with behavioral pharmacology of Org-5222, a broad-spectrum antidopaminergic and antiserotonergic compound. European Journal of Pharmacology (Jul 1990) 183(5): 1890-1891. (abstract)
9. Costall B, Domeney AM, Kelly ME, Naylor RJ, Tomkins DM. Actions of Org-5222 as a novel psychotropic agent. Pharmacology Biochemistry and Behavior (Mar 1990) 35(3): 607-615.
10. Arnt J, Hesselink MB, Didriksen M, van der Heijden JA, Feenstra RW, Kruse CG. DU127090: a novel partial dopamine agonist with antipsychotic activity: a putative potent full spectrum antipsychotic with low EPS potential. Schizophrenia Research (Mar 15, 2003) 60(1): 104-104 (Suppl S). (abstract)
11. van Kolfschoten A, Hesselink MB, Long SK, Feenstra RW, Arnt J, Didriksen M, Kruse CG. DU127090: a novel partial dopamine agonist with antipsychotic activity partial agonist character in functional assays in vivo. Schizophrenia Research (Mar 15, 2003) 60(1): 117-117 (Suppl S). (abstract)
12. de Vries M, de Haes JU, Grahnen A, Nyman L, Bergstrom M, Wall A, Langstrom B. DU127090: a novel partial dopamine agonist with antipsychotic activity: pilot study of dopamine D-2 receptor occupancy after multiple oral administration of DU127090 to healthy male volunteers, using C-11-raclopride by means of positron emission tomography. Schizophrenia Research (Mar 15, 2003) 60(1): 239-240 (Suppl S). (abstract)
13. Yang H, Casey DE, Feenstra RW, Kruse CG, Long SK. DU127090: a novel partial dopamine agonist with antipsychotic activity behavioral effects of DU127090 in Cebus non-human primates. Schizophrenia Research (Mar 15, 2003) 60(1): 370-370 (Suppl S). (abstract)
14. Collie IT, Holt JD, Stam N, Roesink C, Hill DR, Shahid M. Binding profile of Org-5222 at cloned human dopamine D-2, D-3 and D-4 receptors. British Journal of Pharmacology (Dec 1995) 116: P380-P380 (Suppl S). (abstract)
15. Broekkamp CLE, Degraaf JS, Vandelft AML. Characterization with behavioral pharmacology of Org-5222, a broad-spectrum antidopaminergic and antiserotonergic compound. European Journal of Pharmacology (Jul 1990) 183(5): 1890-1891. (abstract)
16. Costal Domeney AM, Kelly ME, Naylor RJ, Tomkins DM. Actions of Org-5222 as a novel psychotropic agent. Pharmacology Biochemistry and Behavior (Mar 1990) 35(3): 607-615.
17. Graul AI. Annual update 2003: drugs for psychiatric disorders and substance abuse. Drugs of the Future (Nov 2003) 28(11): 1103-1121.
18. Suzuki H, Morokawa Y, Gen K, Takagi H, Yamaguchi N, Tanaka C, Aoba A. The relationship between the daily dose, the plasma concentration of AD-5423 (blonanserin), and its plasma anti-dopamine (D-2) and anti-serotonin (5-HT2A) activity, and the plasma serotonin/-dopamine (S/D) ratio. International Clinical Psychopharmacology (May 2003) 18(3): 187-187. (abstract)
19. Nagai T, Noda Y, Une T, Furukawa K, Furukawa H, Kan QM, Nabeshima T. Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice. Neuroreport (Feb 10, 2003) 14(2): 269-272.
20. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods and Findings in Experimental and Clinical Pharmacology (Nov 2002) 24(9): 615-643.
21. Mealy NE, Castaner R, Martin L, del Fresno M, Revel L, Bayes M, Stringer M, Sorbera LA, Cole P, Cullell-Young M, Leeson PA, Prous J. Annual review 2002 - Psychopharmacologic drugs. Drugs of the Future (Oct 2002) 27(10): 995-1018.
22. Suzuki K, Hiyama Y, Une T, Fujiwara I. Crystal structure of an antipsychotic agent, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenil)-5,6,7,8,9,10- hexahydrocycloocta[b]pyridine (blonanserin). Analytical Sciences (Nov 2002) 18(11): 1289-1290.
23. Yokota K, Tatebayashi H, Matsuo T, Shoge T, Motomura H, Matsuno T, Fukuda A, Tashiro N. The effects of neuroleptics on the GABA-induced Cl-current in rat dorsal root ganglion neurons: differences between some neuroleptics. British Journal of Pharmacology (Mar 2002) 135(6): 1547-1555.
24. Barr AM, Lehmann-Masten V, Paulus M, Gainetdinov RR, Caron MG, Geyer MA. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology (Feb 2004) 29(2): 221-228.
25. Winstanley CA, Chudasama Y, Dalley JW, Theobald DEH, Glennon JC, Robbins TW. Intra-prefrontal S-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology (May 2003) 167(3): 304-314.
26. Habara T, Hamamura M, Miki M, Ohashi K, Fujiwara Y, Kuroda S. M100907, a selective 5-HT2A receptor antagonist, attenuates phencyclidine-induced Fos expression in discrete regions of rat brain. International Clinical Psychopharmacology (Aug 2002) 17: S122-S122 (Suppl 2). (abstract)
27. Potkin SG, Shipley J, Bera RB, Carreon D, Fallon J, Alva G, Keator D. Clinical and pet effects of M100907, a selective 5HT-2A receptor antagonist. Schizophrenia Research (Apr 15, 2001) 49(1-2): 242-242 Sp. Iss. SI (Suppl). (abstract)
28. Geyer, MA, Krebs-Thomson K, Varty GB: The effects of M100907 in pharmacological and developmental animal models of prepulse inhibition deficits in schizophrenia. Neuropsychopharmacology (Dec 1999) 21(6): S134-S142 (Suppl S).
29. Corbett R, Zhou L, Sorensen SM, Mondadori C. Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice. Neuropsychopharmacology (Dec 1999) 21(6): S211-S218 (Suppl).
30. Talvik-Lotfi M, Nyberg S, Nordstrom AL, Ito H, Halldin C, Brunner F, Farde L. A high central 5HT(2A) a receptor occupancy in M100907-treated schizophrenic patients demonstrated with pet and [C-11] M100907. Schizophrenia Research (Apr 1999) 36(1-3): 109-110 Sp Iss SI. (Abstract)
31. Seeman P, Guan HC, Van Tol HH. Dopamine D4 receptors elevated in schizophrenia. Nature 1993; 365: 441-445.
32. Danysz W. Sonepiprazole. Curr Opin CPNS Invest Drugs 2000; 2: 97-104.
33. Mansbach RS, Brooks EW, Sanner MA, et al. Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of pre-pulse inhibition. Psychopharmacology 1998; 135: 194-200.
34. Corrigan MH, Gallen CC, Bonura ML, Merchant KM. Effectiveness of the selective D-r antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Biological Psychiatry (Mar 1, 2004) 55(5): 445-451.
35. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad-spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001; 25(6): 904-914.
36. Kalkman HO, Matkovits-Gupta T, Alphs L. Preclinical profile of iloperidone: data published by Novartis Pharmaceuticals.
37. Potkin S, Alva G, Bera R, Young F, Gharabawi. Effect of iloperidone on cerebral metabolism in patients. Abstract # 0022-04.
38. Cucchiaro J, Lasser R, Fairweather D, Nann-Vernotica E, Gharabawi G. Risk/benefit assessment of iloperidone in the treatment of psychotic disorders: a prospective double-blind, randomized, parallel-group, placebo-controlled study: Abstract by Novartis Pharmaceuticals.
39. Matkovits-Gupta T, Cucchiaro J, El-Bizri H, Fairweather D, Klonowski E, Lasser R, Nann-Vernotica E, Narurkar M, Pirrozi C, Waltrip R, Young F, Gharabawi G. Safety and efficacy of iloperidone in patients with psychotic disorders: A randomized, double-blind multicenter study. Schizophrenia Research (Apr 15, 2001) 49(1-2): 238-238 Sp Iss SI Suppl S. (abstract)
40. Cutler NR, Shipley JE, Varaklis J, Hourani J, Jhee SS, Sramek JJ. Bridging study of iloperidone in schizophrenic inpatients. Psychopharmacology Bulletin 1996; 32(3): 428-428. (abstract)
41. Szewczak MR, Corbett R, Rush DK, Wilmot CA, Conway PG, Strupczewski JT, Cornfeldt M. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. Journal of Pharmacology and Experimental Therapeutics (Sept 1995) 274(3): 1404-1413.
42. Strupczewski JT, Bordeau KJ, Glamkowski EJ, Fink DM, Bregna DE, Corbett R, Hartman HB, Roehr JE, Szewczak MR, Woods AT. Antipsychotic activity of 1,2-benzisothiazole analogs of the potential atypical antipsychotic iloperidone (HP873). Abstracts of Papers of the American Chemical Society (Aug 20, 1995) 210: 138-MEDI Part 2.
43. Sainati SM, Hubbard JW, Chi E, Grasing K, Brecher MB. Safety, tolerability and effect of food on the pharmacokinetics of iloperidone (HP-873), a potential atypical antipsychotic. Journal of Clinical Pharmacology (Jul 1995) 35(7): 713-720.
44. Mealy NE, Castaner R, Martin L, del Fresno M, Revel L, Bayes M, Stringer M, Sorbera LA, Cole P, Cullell-Young M, Leeson PA, Prous J. Annual review 2002 - Psychopharmacologic drugs. Drugs of the Future (Oct 2002) 27(10): 995-1018.
45. Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, Millan MJ. Comparison of hippocampal G protein activation by 5-HT1A receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn-Schmiedebergs Archives of Pharmacology (Sep 2003) 368(3): 188-199.
46. Dekeyne A, Rivet JM, Gobert A, Millan MJ. Generalization of serotonin (5-HT)(1A) agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD 128,907 and 7-OH-DPAT. Neuropharmacology (Jun 2001) 40(7): 899-910.
47. Cussac D, Newman-Tancredi A, Nicolas JP, Boulin JA, Millan MJ. Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol. Naunyn-Schmiedebergs Archives of Pharmacology (May 2000) 361(5): 549-554.
48. Rosenthal MH, Bryant SL. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clinical Neuropharmacology (Jan-Feb 2004) 27(1): 38-43.
49. Spence S, Green R, Hunter M. Modafinil modulates prefrontal function in schizophrenia. Schizophrenia Research (Feb 15, 2004) 67(1): 265-265 (Suppl S). (abstract)
50. Rosenthal MH, Bryant S. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Schizophrenia Research (Mar 15, 2003) 60(1): 301-301 (Suppl S). (abstract)
51. Investor Relations - Pharmaceutical Pipeline. Johnson & Johnson. Company World Wide Web site, 2004, Apr 13.
52. Johnson & Johnson - Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Devices Conference. Johnson & Johnson. Company presentation 2004, Feb 04.
53. WHO Drug Information 2001; 15: 1.
54. Clinical Trials, gov - Information on Clinical Trials and Human Research Studies...: ...Trial evaluating the safety and efficacy of 2 doses of ER OROS Paliperidone in acute adult schizophrenics...
55. Owen RT, Blenkinsopp J, Leysen JE. Receptor interactions of new antipsychotics Leysen JE, et al. International Journal of Psychiatry in Clinical Practice 1998; (Suppl 2): S3-S17[1[ (multiple letters).
56. International Journal of Psychiatry in Clinical Practice 1999; 3(1): 63.
57. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer general compounds. Life Sciences 2000; 68(1): 29-39.
58. Carlsson ML: Experimental hypoglutamatergia model for cognitive deficits of schizophrenia: Effects of classical neuroleptics, 5-HT2A receptor-blocking antipsychotics, the ampakine CX516 and the dopaminergic stabilizer ACR16. European Neuropsychopharmacology (Oct 3, 2002) 12: S167-S168 (Suppl) (abstract)
59. Marenco S, Egan MF, Goldberg TE, Knable MB, McClure RK, Winterer G, Weinberger DR. Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: A case series. Schizophrenia Research (Oct 1, 2002) 57(2-3): 221-226.
60. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, Lynch G. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. Journal of Clinical Psychopharmacology (Oct 2001) 21(5): 484-487.
61. Hampson RE, Rogers G, Lynch G, Deadwyler SA. Effects of the ampakine CX516 on memory. Journal of Neurochemistry (2000) 74: S49-S49 (Suppl S) (abstract)
62. 493923. Product Development. Protarga Inc. Company World Wide Web Site (Dec 31, 2002).
63. Ichikawa J, Meltzer HY. 352899: Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. European Archives of Psychiatry and Clinical Neuroscience 1999; 249(Suppl 4): IV90-IV98.
64. Meltzer HY. 73584: Novell approaches to the pharmacotherapy of schizophrenia. Drug Development Research 1986; 9(1): 23-40.
65. Shiigi Y, Fujimura M, Kuriyama M, Morimoto T, Hashimoto K, Tanaka H, Takehara S, Yamagami K. Y-931, a novel antipsychotic with potential property to ameliorate NMDA receptor-Hypofunction: II further characterization in comparison with clozapine and haloperidol. Society of Neuroscience Abstracts 2000; 26(1). (abstract 97. 16.)
66. Weldife Corp: Drug Development Pipeline. Y-931. Company Communication (Oct 12, 2000).
67. Tanaka H, Kimura K, Horluchi H, Kohara T, Fujimura M, Hashimoto K, Yasumatsu H, Morimoto T, Yamagami K, Arita M. Y0931, a novel antipsychotic with potential anti-NRH (NMDA receptor-hypofunction) activity: Synthesis and structure-activity relationships of 6H-[1]benzothieno[2,3-B][1,5]. International Symposium on Medicinal Chemistry 2000; 16th September 18-22: PB128.
68. Drysdale AJ, Platt B. 527530: Cannabinoids: Mechanisms and therapeutic applications in the CNS. Current Medicinal Chemistry 2003; 10(24): 2719-2732.
69. Jarbe TUC, DiPatrizio NV, Li C, Makriyannis A. 527535: The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist ®-methanandamide in rats. Pharmacology Biochemistry and Behavior 2003; 75(4): 809-821.
70. Buck SH, ed. The tachykinin receptors. Totowa, New Jersey, USA: Humana Press, 1994.
71. National Alliance for the Mentally Ill Newsline (Nov-Dec 2003).